Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma — Myeloma Research News

Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from two clinical trials show. The findings were presented at the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting, held Sept. 11–14 in Houston, Texas. Ygalo is a lipophilic peptide-conjugated alkylator developed…

Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma — Myeloma Research News

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.